<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015352</url>
  </required_header>
  <id_info>
    <org_study_id>GFM-Aza-Epo-2008-01</org_study_id>
    <nct_id>NCT01015352</nct_id>
  </id_info>
  <brief_title>Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)</brief_title>
  <official_title>A Phase II Study of Azacitidine (Vidaza®) Combined to Epoetin Beta (NeoRecormon®) in IPSS Low-risk and Intermediate-1 MDS Patients, Resistant to ESA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to treat low-risk MDS patients,who are dependent on red-blood cell&#xD;
      transfusion due to disease-related anemia, and who have a proven resistance towards treatment&#xD;
      with erythropoetin-stimulating agents (ESA). The study randomizes patients to receive a&#xD;
      treatment with the demethylating agent 5-azacytidine alone or in combination with an ESA. The&#xD;
      study thus evaluates, if efficacy of 5-azacytidine, notably on the red-blood cell&#xD;
      transfusion-dependence is comparable/inferior to a combination treatment with azacitidine and&#xD;
      an ESA (that is if 5-azacytidine can overcome the resistance towards ESA). Being a phase II&#xD;
      study, the study assesses, duration of erythroid response, overall survival and time to&#xD;
      progression as well as toxicity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II Study of Azacitidine (Vidaza®) Combined to Epoetin Beta (NeoRecormon®) in IPSS&#xD;
      Low-risk and Intermediate-1 MDS Patients, Resistant to ESA&#xD;
&#xD;
      The Primary Endpoint of this study is to determine the major erythroid response rate after 6&#xD;
      courses, assessed according to IWG 2000 criteria.&#xD;
&#xD;
      The Secondary Endpoints are to determine the percentage of major HI-E and minor HI-E after 4&#xD;
      and 6 courses according to IWG 2000, the HI-E IWG 2006 criteria, the duration of erythroid&#xD;
      response, the red blood cell transfusion independence at 4 and 6 months, the overall survival&#xD;
      and time to IPSS progression and the toxicity (NCI-CTAE).&#xD;
&#xD;
      The trial will enroll 98 patients (49 patients per arm)&#xD;
&#xD;
      Treatment in arm A:&#xD;
&#xD;
      Azacitidine 75mg/sqm SQ per day for 5 days every 28 days for 6 courses Dosing of each&#xD;
      subsequent course will be adapted according to extrahematological toxicity and cytopenias.&#xD;
&#xD;
      In responders after 6 courses of azacitidine according to IWG 2000 criteria (both minor and&#xD;
      major erythroid responses of HI-E) 12 identical additional maintenance courses will be&#xD;
      delivered every 28 days, unless relapse occurs (according to IWG 2000 criteria).&#xD;
&#xD;
      Treatment in arm B:&#xD;
&#xD;
      • Azacitidine 75mg/sqm SQ per day for 5 days every 28 days for 6 courses.&#xD;
&#xD;
      (dosing of each subsequent course will be adapted according to extra hematological toxicity&#xD;
      and cytopenias) AND&#xD;
&#xD;
      • Epoetin beta : 60000U weekly SQ injections Dosing of epoetin beta will be adapted according&#xD;
      to current ASH-ASCO guidelines and black box warning of epoetin beta. Epoetin beta therapy&#xD;
      may therefore be interrupted, in case of response to azacitidine, as soon as a hemoglobin&#xD;
      level of 12g/dl is achieved on two sequential bimonthly blood count measurements.&#xD;
&#xD;
      A 40% dose reduction of epoetin beta will be required if:&#xD;
&#xD;
        -  Hb level rise of 1 g/dl is observed within two weeks&#xD;
&#xD;
        -  Hb level exceeds 11g/dl&#xD;
&#xD;
      In responders after 6 courses of azacitidine + epoetin beta, according to IWG 2000 criteria&#xD;
      (both minor and major erythroid responses of HI-E) 12 identical additional maintenance&#xD;
      courses of azacitidine will be delivered every 28 days, unless relapse occurs (according to&#xD;
      IWG 2000 criteria) Epoetin beta will be administered as described above.&#xD;
&#xD;
      In both arms, each subsequent course will be delivered&#xD;
&#xD;
        -  In absence of persistent grade &gt;2 non-hematological toxicity&#xD;
&#xD;
        -  In absence of rehospitalisation for severe bleeding, infection or febrile neutropenia&#xD;
           and non-hematological toxicity following the previous course&#xD;
&#xD;
        -  If neutrophil counts are &gt; 1G/l or &gt; 50% of baseline neutrophil counts&#xD;
&#xD;
        -  If platelets are &gt; 75G/l or &gt; 50% of baseline platelets counts&#xD;
&#xD;
      In case of persistent cytopenia, blood counts will be at least checked every 2 weeks, and the&#xD;
      next course delayed until resolution of cytopenia, as defined above.&#xD;
&#xD;
      In case of persistence of cytopenia beyond day 56 of the preceding course, an new evaluation&#xD;
      of the disease, using clinical examination, blood and bone marrow examinations +/-&#xD;
      cytogenetics will be mandatory before eventually pursuing azacitidine at lower dosing levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the major erythroid response rate after 6 courses, assessed according to IWG 2000 criteria</measure>
    <time_frame>after 6 courses of treatment in the respective treatment arm</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree and duration of erythroid response (including red blood cell transfusion independence),overall survival and time to progression and toxicity</measure>
    <time_frame>after 4 and 6 months of treatment until the end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Azacitidine 75mg/sqm SQ per day for 5 days every 28 days for 6 courses and 12 additional maintenance courses in responders.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Azacitidine: 75mg/sqm SQ per day for 5 days every 28 days for 6 courses AND&#xD;
Epoetin beta : 60000U weekly SQ injections (to be adapted according to Hb as described above)&#xD;
12 additional maintenance courses are planned in responders</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine 75mg/sqm SQ per day for 5 days every 28 days</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Vidaza®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin beta</intervention_name>
    <description>Epoetin beta : 60000U weekly SQ injections&#xD;
NeoRecormon®</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Epoetin beta : 60000U weekly SQ injections</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        MDS defined as&#xD;
&#xD;
          -  RCMD, RA with or without ring sideroblasts&#xD;
&#xD;
          -  RAEB 1, or CMML 1, if WBC &lt; 13 G /l according to the WHO classification&#xD;
&#xD;
          -  with a low or int-1 IPSS score AND&#xD;
&#xD;
          -  primary or secondary resistance to epoetin alpha/ beta (&gt; 60000 U/w) or darbepoetin (&gt;&#xD;
             250ug/w), administered for at least 12 weeks&#xD;
&#xD;
          -  requirement of RBC transfusions &gt; 4 U in the previous 8 weeks&#xD;
&#xD;
          -  Aged 18 years or more&#xD;
&#xD;
          -  Adequate contraception, if relevant&#xD;
&#xD;
          -  Negative pregnancy test if relevant&#xD;
&#xD;
          -  Written Informed consent&#xD;
&#xD;
          -  Ability to participate to a clinical trial and adhere to study procedures&#xD;
&#xD;
          -  Health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Therapy-related MDS (after chemo- or radiotherapy for a previous neoplasm or immune&#xD;
             disorder)&#xD;
&#xD;
          -  Patients with a planned allogeneic bone marrow transplantation&#xD;
&#xD;
          -  Creatininemia &gt;1.5 upper normal value or estimated Ccr less than 30ml/mn&#xD;
&#xD;
          -  ALAT and ASAT &gt;2.5 upper normal value&#xD;
&#xD;
          -  Bilirubin &gt;2N, except unconjugated hyperbilirubinemia due to MDS-related&#xD;
             dyserythropoiesis&#xD;
&#xD;
          -  Heart failure NYHA &gt; II&#xD;
&#xD;
          -  Known allergy to mannitol&#xD;
&#xD;
          -  Other tumor, unstable for the last three years, except in situ uterine carcinoma or&#xD;
             basal skin tumor&#xD;
&#xD;
          -  ECOG &gt; 2&#xD;
&#xD;
          -  Life expectancy less than 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simone Boehrer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Francophone des Myélodysplasies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claude Gardin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Francophone des Myélodysplasies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Boulogne Sur Mer</name>
      <address>
        <city>Boulogne Sur Mer</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Clémenceau</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital le Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital kremlin Bicêtre</name>
      <address>
        <city>Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Vincent</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Archet1</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Source</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Maréchal Joffre</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean-Bernard</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gfmgroup.org</url>
    <description>(Website of the french group of MDS)</description>
  </link>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>March 18, 2014</last_update_submitted>
  <last_update_submitted_qc>March 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

